Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections

INTRODUCTION: Infections caused by multidrug-resistant (MDR), extensively drug-resistant (XDR), and difficult-to-treat (DTR) Pseudomonas aeruginosa are increasingly challenging to combat. Ceftolozane–tazobactam (C/T) is a novel β-lactam–β-lactamase inhibitor combination now commonly used to treat MD...

Descripción completa

Detalles Bibliográficos
Autores principales: Holger, Dana J., Rebold, Nicholas S., Alosaimy, Sara, Morrisette, Taylor, Lagnf, Abdalhamid, Belza, Ana Christine, Coyne, Ashlan J. Kunz, El Ghali, Amer, Veve, Michael P., Rybak, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617978/
https://www.ncbi.nlm.nih.gov/pubmed/36048335
http://dx.doi.org/10.1007/s40121-022-00687-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617978/
https://www.ncbi.nlm.nih.gov/pubmed/36048335
http://dx.doi.org/10.1007/s40121-022-00687-9

Ejemplares similares